In a regulatory filing, Zynga disclosed that its CEO Frank Gibeau sold 500K shares of common stock on March 1st in a total transaction size of $5.73M, reducing his stake by about 39%.

In a regulatory filing, Snap disclosed that its CEO Evan Spiegel sold 1.54M shares of common stock on March 1st in a total transaction size of $100.1M, reducing his stake by about 3%.

This is the lowest level of holdings since May 11th, 2020.

The U.S. Food and Drug Administration approved Pfizer's supplemental New Drug Application for LORBRENA, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase-positive non-small cell lung cancer. LORBRENA is now indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test. The FDA action also converts the 2018 accelerated approval to full approval. The application was approved under the FDA's Real-Time Oncology Review pilot program. "For more than a decade, Pfizer has been a pioneer in delivering biomarker-driven therapies and addressing the diverse and evolving needs of people with non-small cell lung cancer," said Andy Schmeltz, Global President, Pfizer Oncology. "LORBRENA has been a transformative medicine for people with ALK-positive advanced NSCLC, and this FDA approval in the first-line setting means that we can now extend hope to even more people."

Qualys issued an update on the security incident regarding the Accellion FTA file transfer solution. "Qualys received new information about a previously identified zero-day exploit in a third-party solution, Accellion FTA that Qualys deployed to transfer files as part of our customer support system," the company said. "Qualys confirms today there is no impact on the Qualys production environments, codebase or customer data hosted on the Qualys Cloud Platform. All Qualys platforms continue to be fully functional and at no time was there any operational impact. Qualys had deployed the Accellion FTA server in a segregated DMZ environment, completely separate from systems that host and support Qualys products to transfer information as part of our customer support system. Qualys chose the Accellion FTA solution for encrypted temporary transfer of manually uploaded files. There was no connectivity between the Accellion FTA server and our production customer data environment (the Qualys Cloud Platform). The Accellion FTA product is a third-party system fully managed by Accellion. As with any security incident, the investigation is ongoing, and we continue to look for ways to enhance security and provide the strongest protections for our customers. We have engaged FireEye Mandiant, who also worked with Accellion on the wider investigation. Qualys is strongly committed to the security of its customers and their data, and we will notify them should material information become available."

In an interview on CNBC's Mad Money, Todd Penegor said the company's breakfast business is doing "quite well" with strong repeat customers. Wendy's is seeing a lot more mobile ordering and the loyalty program will help drive the digital mix, he added. Currently, 90% of the business is going through the drive through lanes. When dining rooms open, pressure on the drive through should subside, Penegor noted.

In a regulatory filing, Kiniksa stated: "In September 2017, Kiniksa entered into a License Agreement with Regeneron Pharmaceuticals (REGN), pursuant to which Regeneron granted the company an exclusive license under certain intellectual property rights controlled by Regeneron to develop and commercialize rilonacept for the Kiniksa field and within the territory described therein. Pursuant to an Asset Transfer Agreement between the company and Kiniksa Pharmaceuticals Ltd., a wholly-owned subsidiary of the company, the company assigned the License Agreement to Kiniksa UK in January 2021. In accordance with the License Agreement, Kiniksa UK entered into a Commercial Supply Agreement with Regeneron on March 1, 2021, pursuant to which Regeneron has the exclusive right to manufacture and supply rilonacept for Kiniksa UK's requirements, which Kiniksa UK may use for its clinical development and commercialization activities. The purchase price and payment terms in the Supply Agreement are in accordance with the terms set forth in the License Agreement."

LGI Homes announced 764 home closings in February 2021, up from 606 home closings in February 2020, representing year-over-year growth of 26.1%. The company ended the first two months of 2021 with 1,414 home closings, a 36.0% increase over 1,040 home closings during the first two months of 2020. As of the end of February 2021, the company had 103 active selling communities.

In a regulatory filing, Azek CEO and president Jesse G. Singh disclosed the sale of 55,000 class A common shares of the company on March 1 at a price of $44.86 per share.

Consensus is $790.42M. According to the company's records, Q1 revenue in 2019 was $886.3M and in 2020 was $551.7M.